Strategic partnerships Sen-Jam has a track record of collaborations with industry players like Mallinckrodt and KVK Tech to advance anti-inflammatory formulations and COVID-19 therapies, signaling openness to CDMO and co-development opportunities that can expand its market reach.

Clinical momentum With FDA-pending products and a multi-indication patent portfolio targeting inflammation and flu-like symptoms, there are near-term upsell opportunities in trials, regulatory consulting support, and potential advisory roles to accelerate development timelines.

Investors and capital Recent investment from 5 Horizons Capital and ongoing fundraising activity suggest a favorable window for strategic partnerships that leverage funding to scale clinical programs, manufacturing capabilities, and market access initiatives.

Executive and advisory depth Expansion of the Scientific Advisory Board with immunology and infectious disease expertise enhances credibility for partnering with larger pharma on joint development, licensing deals, and translational programs.

Global-ready operations Existing tech stack and outsourcing collaborations indicate readiness for scalable manufacturing and distribution partnerships, including formulation development, CMC support, and potential OTC/RA pathways to broaden commercialization.